|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sher T, Dy GK and Adjei AA: Small cell
lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Horn L and Pao W: EML4-ALK: Honing in on a
new target in non-small-cell lung cancer. J Clin Oncol.
27:4232–4235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inamura K, Takeuchi K, Togashi Y, Nomura
K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, et
al: EML4-ALK fusion is linked to histological characteristics in a
subset of lung cancers. J Thorac Oncol. 3:13–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perner S, Wagner PL, Demichelis F, Mehra
R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W,
Giordano TJ, et al: EML4-ALK fusion lung cancer: A rare acquired
event. Neoplasia. 10:298–302. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wong DW, Leung EL, So KK, Tam IY, Sihoe
AD, Cheng LC, Ho KK, Au JS, Chung LP and Pik Wong M: University of
Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is
involved in various histologic types of lung cancers from
nonsmokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, et al: Clinical features and outcome of patients with
non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.
27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martelli MP, Sozzi G, Hernandez L,
Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P,
Pastorino U, et al: EML4-ALK rearrangement in non-small cell lung
cancer and non-tumor lung tissues. Am J Pathol. 174:661–670. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sasaki T, Rodig SJ, Chirieac LR and Jänne
PA: The biology and treatment of EML4-ALK non-small cell lung
cancer. Eur J Cancer. 46:1773–1780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diasio RB and Johnson MR: The role of
pharmacogenetics and pharmacogenomics in cancer chemotherapy with
5-fluorouracil. Pharmacology. 61:199–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukushima M, Morita M, Ikeda K and
Nagayama S: Population study of expression of thymidylate synthase
and dihydropyrimidine dehydrogenase in patients with solid tumors.
Int J Mol Med. 12:839–844. 2003.PubMed/NCBI
|
|
13
|
Chu E, Copur SM, Ju J, Chen TM, Khleif S,
Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F and Allegra CJ:
Thymidylate synthase protein and p53 mRNA form an in vivo
ribonucleoprotein complex. Mol Cell Biol. 19:1582–1594.
1999.PubMed/NCBI
|
|
14
|
Kawakami K, Graziano F, Watanabe G, Ruzzo
A, Santini D, Catalano V, Bisonni R, Arduini F, Bearzi I, Cascinu
S, et al: Prognostic role of thymidylate synthase polymorphisms in
gastric cancer patients treated with surgery and adjuvant
chemotherapy. Clin Cancer Res. 11:3778–3783. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Righi L, Papotti MG, Ceppi P, Billè A,
Bacillo E, Molinaro L, Ruffini E, Scagliotti GV and Selvaggi G:
Thymidylate synthase but not excision repair cross-complementation
group 1 tumor expression predicts outcome in patients with
malignant pleural mesothelioma treated with pemetrexed-based
chemotherapy. J Clin Oncol. 28:1534–1539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gomez HL, Santillana SL, Vallejos CS,
Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ,
Niyikiza C and Hanauske AR: A phase II trial of pemetrexed in
advanced breast cancer: Clinical response and association with
molecular target expression. Clin Cancer Res. 12:832–838. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kwak EL, Bang YJ, Camidge DR, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim DW, Ahn MJ, Shi YK, et al: Updated
results of a global phase II study with crizotinib in advanced
ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol.
30:(Suppl): abstr. 75332012. View Article : Google Scholar
|
|
19
|
Shaw AT, Kim DW, Nakagawa K, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi YL, Soda M, Yamashita Y, Ueno T,
Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H,
et al: ALK Lung Cancer Study Group: EML4-ALK mutations in lung
cancer that confer resistance to ALK inhibitors. N Engl J Med.
363:1734–1739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey
of phosphotyrosine signaling identifies oncogenic kinases in lung
cancer. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Zhang S, Yang X, Yang J, Zhou Q,
Yin L, An S, Lin J, Chen S, Xie Z, et al: Fusion of EML4 and ALK is
associated with development of lung adenocarcinomas lacking EGFR
and KRAS mutations and is correlated with ALK expression. Mol
Cancer. 9:1882010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B,
Han X, Tian W, Pao W, Chen H and Ji H: Lung adenocarcinoma from
East Asian never-smokers is a disease largely defined by targetable
oncogenic mutant kinases. J Clin Oncol. 28:4616–4620. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gandara DR, Huang E and Desai S:
Thymidylate synthase (TS) gene expression in patients with ALK
positive(+) non-small cell lung cancer (NSCLC): Implications for
therapy. J Clin Oncol. 30:(Suppl). a75822012.
|
